Most Surveyed Clinicians Will Prescribe Amgen/GlaxoSmithKline’s Prolia As Either A Second Or Third Line Therapy For Osteoporosis

Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that the majority of surveyed clinicians say they will use Amgen/GlaxoSmithKline’s Prolia as either a second- or third-line therapy for osteoporosis if the drug receives regulatory approval for the indication…

source : www.medicalnewstoday.com

Related News:

• FDA Okays New Hypertension Polypill
• Quitting smoking may minimize harmful bacteria and replenish healthy bacteria
• World’s Largest Study On Insulin Therapy Completes Recruitment With 60,000 Patients
• Mayo Clinic Health Letter Offers Overview Of Meningioma — Brain Tumor That May Not Need Treatment
• Use Of Nanoparticles To Shrink Tumors In Mice Holds Important Implications For Cancer Therapy
• Music Therapy Has Some Benefits in Stroke Recovery
• What Affects The Gastrointestinal Symptoms In Peritoneal Dialysis Patients?
• Gene therapy a step closer to mass production
• New Scientific Statement Evaluates Benefits And Risks Of Menopausal Hormone Therapy
• ENB-0040, A Bone Targeted Enzyme Replacement Therapy, Shows Promise In Children With Hypophosphatasia

Details :
Submited at Friday, December 4th, 2009 at 1:00 pm on Orthopaedic by robert
Comment RSS 2.0 - leave a comment - trackback